Outlook 2018: Pharma/Life Sciences Law and Policy

January 3, 2018

Will the 21st Century Cures Act further its aim to boost drug and device development in 2018? That is one of the questions the life sciences industry and attorneys are asking for the new year. The law provides extra money for research and development—including ambitious research into cancer and a landmark precision medicine project involving 1 million Americans—and spurs more use of real-world evidence to support product approvals.

Related Stories